Patents Assigned to Instituto Nazionale Tumori
  • MARKERS OF MELANOMA AND USES THEREOF
    Publication number: 20130316931
    Abstract: The invention relates to a method for determining prognosis, predicting or monitoring response to therapy of patients affected by melanoma through the evaluation of the methylation of different genomic DNA sequences, including the Long Interspersed Nucleotide Element-1 (LINE-1) repetitive DNA sequences and/or the concomitant methylation profile of specific groups of genes defined as methylation signature.
    Type: Application
    Filed: February 1, 2012
    Publication date: November 28, 2013
    Applicants: CENTRO DI RIFERIMENTO ONCOLOGICO-INSTITUTO NAZIONALE TUMORI-AVIANO, AZIENDA OSPEDALIERA UNIVERSITARIA SENESE
    Inventors: Luca Sigalotti, Michele Maio
  • Gene expression markers for predicting response to chemotherapy
    Patent number: 7871769
    Abstract: The present invention provides sets of genes the expression of which is important in the prognosis of cancer. In particular, the invention provides gene expression information useful for predicting whether cancer patients are likely to have a beneficial treatment response to chemotherapy FHIT; MTA1; ErbB4; FUS; BBC3; IGF1R; CD9; TP53BP1; MUC1; IGFBP5; rhoC; RALBP1; STAT3; ERK1; SGCB; DHPS; MGMT; CRIP2; ErbB3; RAP1GDS1; CCND1; PRKCD; Hepsin; AK055699; ZNF38; SEMA3F; COL1A1; BAG1; AKT1; COL1A2; Wnt.5a; PTPD1; RAB6C; GSTM1, BCL2, ESR1; or the corresponding expression product, is determined, said report includes a prediction that said subject has a decreased likelihood of response to chemotherapy.
    Type: Grant
    Filed: April 7, 2005
    Date of Patent: January 18, 2011
    Assignees: Genomic Health, Inc., Instituto Nazionale Tumori
    Inventors: Joffre B. Baker, Steven Shak, Luca Gianni